Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament |
Trials |
|
|
clinical deterioration | clinical improvement | deaths | PCR-negative conversion |
RNA vaccine | 3 | - | - | 0.50 [0.11; 2.28], 2 RCTs, I2=0% inconclusive result | - | |
Non replicating viral vector | 2 | - | - | 0.20 [0.02; 1.72], 1 RCT, I2=0% inconclusive result | - | |
Inactivated virus vaccine | 1 | - | - | - | - | |
Ad26.COV2.S A EFFACER | 0 | - | - | - | - | |
BBV152 | 0 | - | - | - | - | |
BCG vaccination | 0 | - | - | - | - | |
CureVac | 0 | - | - | - | - | |
DNA vaccine | 0 | - | - | - | - | |
protein subunit vaccine | 0 | - | - | - | - | |
Sanofi/GSK recombinant protein vaccine | 0 | - | - | - | - | |
SCB-2019 | 0 | - | - | - | - | |
virus-like particles vaccine | 0 | - | - | - | - | |
Zy-Cov-D (Zydus Cadila) | 0 | - | - | - | - | |